Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice.

ABSTRACT:

Background

Addition of docetaxel to androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been proved to be effective with an overall survival (OS) benefit in phase III clinical trials. The effectiveness of docetaxel with ADT in the general patient population remains unknown.

Objective

The purpose of this study is to report the clinical experience in mHSPC patients treated with 3rd-weekly docetaxel plus ADT in routine practice at two Danish institutions.

Design setting and participants

A two-center retrospective study including consecutive mHSPC patients treated with 3rd-weekly docetaxel plus ADT was conducted.

Outcome measurements and statistical analysis

Outcomes of interest were OS, and biochemical a

SUBMITTER: Lendorf ME 

PROVIDER: S-EPMC8317901 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature